Alpha Tau Medical Ltd. (NASDAQ:DRTSW – Get Rating) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 12,000 shares, a decrease of 10.4% from the January 31st total of 13,400 shares. Based on an average daily trading volume, of 25,300 shares, the days-to-cover ratio is presently 0.5 days.

Alpha Tau Medical Stock Performance

Shares of NASDAQ:DRTSW traded up $0.01 during trading on Tuesday, reaching $0.40. 2,100 shares of the company traded hands, compared to its average volume of 18,657. Alpha Tau Medical has a 52 week low of $0.18 and a 52 week high of $1.06. The company's 50 day moving average is $0.38 and its two-hundred day moving average is $0.38.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors and hedge funds have recently bought and sold shares of the company. Polar Asset Management Partners Inc. acquired a new position in shares of Alpha Tau Medical in the 1st quarter valued at approximately $134,000. Walleye Capital LLC bought a new position in Alpha Tau Medical in the first quarter valued at approximately $112,000. Whitebox Advisors LLC acquired a new position in Alpha Tau Medical during the third quarter valued at approximately $65,000. Chicago Partners Investment Group LLC bought a new stake in Alpha Tau Medical during the first quarter worth $55,000. Finally, Walleye Trading LLC acquired a new stake in shares of Alpha Tau Medical in the 1st quarter valued at $65,000.

Alpha Tau Medical Company Profile

(Get Rating)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, lung, and prostate cancers.

Recommended Stories

• Get a free copy of the StockNews.com research report on Alpha Tau Medical (DRTSW)
• Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
• Market Gets "Powelled": S&P 500 Confirms Resistance
• Ulta Insiders Hold Tight: Sell-Siders Buy
• Rivian Plummets, But Is This 2023's Greatest Buying Opportunity?
• Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.